Drug Profile
Dexmethylphenidate - Celgene/Novartis
Alternative Names: d-methylphenidate; D-methylphenidate hydrochloride; D-MPH; Dexmethylphenidate; Dexmethylphenidate hydrochloride; Focalin; Focalin XRLatest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Developer Celgene Corporation; Novartis
- Class Behavioural disorder therapies; Phenylacetates; Piperidines; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Dopamine uptake inhibitors; Neurokinin 1 antagonists; Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder
- Discontinued Fatigue
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 11 Feb 2019 Recro Gainesville entered into a manufacturing and supply agreement with Novartis Pharma for Ritalin LA and Focalin XR capsules
- 05 Nov 2015 Par Pharmaceutical Inc has been acquired by Endo International